RAP-219
Phase 2Recruiting 2 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bipolar 1 Disorder
Conditions
Bipolar 1 Disorder
Trial Timeline
Jul 25, 2025 → Dec 1, 2026
NCT ID
NCT07046494About RAP-219
RAP-219 is a phase 2 stage product being developed by Rapport Therapeutics for Bipolar 1 Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07046494. Target conditions include Bipolar 1 Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Bipolar 1 Disorder were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07219407 | Phase 2 | Recruiting |
| NCT07046494 | Phase 2 | Recruiting |
| NCT06377930 | Phase 2 | Completed |
Competing Products
20 competing products in Bipolar 1 Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine | Eli Lilly | Phase 3 | 32 |
| Valproate + Lithium + Risperidone + Olanzapine | Eli Lilly | Phase 3 | 40 |
| Olanzapine + Placebo | Eli Lilly | Approved | 43 |
| FK949E | Astellas Pharma | Phase 3 | 40 |
| FK949E | Astellas Pharma | Phase 3 | 40 |
| FK949E + Placebo | Astellas Pharma | Phase 2/3 | 38 |
| Escitalopram + Bupropion XL | Lupin Limited | Phase 3 | 32 |
| Olanzapine | Eli Lilly | Approved | 43 |
| Olanzapine Hydrochloride + Lithium Carbonate | Eli Lilly | Phase 3 | 40 |
| olanzapine + lithium + valproate + carbamazepine | Eli Lilly | Phase 3 | 40 |
| Olanzapine | Eli Lilly | Approved | 43 |
| Olanzapine | Eli Lilly | Phase 3 | 40 |
| LY2979165 + Placebo | Eli Lilly | Phase 1 | 29 |
| olanzapine + divalproex sodium + placebo | Eli Lilly | Approved | 43 |
| olanzapine + risperidone | Eli Lilly | Approved | 43 |
| LY2979165 + placebo | Eli Lilly | Phase 1 | 29 |
| Topiramate + Placebo | Eli Lilly | Approved | 43 |
| olanzapine | Eli Lilly | Phase 3 | 40 |
| Olanzapine + Placebo | Eli Lilly | Phase 3 | 40 |
| Brenipatide + Placebo | Eli Lilly | Phase 2 | 42 |